Penumbra Q1 2022: Revenue up 20.5% to $203.9M; operating loss of $4.0M vs income of $13.5M

Penumbra Inc

2022-Q1 EPS reported $0.00 revenue$203,895,000

Revenue $203.9M, up 20.5% YoY (21.8% constant currency).
Vascular sales $122.8M (+37.7%); neuro $81.1M (+1.3%).
Gross margin 62.5% vs 65.8% Q1 2021, impacted by labor/logistics costs.
Operating loss $4.0M vs operating income $13.5M in Q1 2021.
SG&A expense $110.9M, up from $79.8M, driving swing to loss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.